ribociclib
novartis
['natalee', ' ribo']
now at #asco23 primary results of #natalee ph3 trial on adjuvant ribocicilb for 3yrs + et for stage ii/iii hr+/her2-neg ebc: on 5101 pts enrolled, ribo was associated with idfs (hr 0.75, p 0.0014), with benefit consistent in all subgroups, and ddfs (hr 0.74) 
MD, Medical Oncologist🇮🇹•Research Fellow at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology